Work

10-year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy: Post-commercialization Study

Year: 2017

Type: article

Source: Journal of the American College of Cardiology

DOI: 10.1016/s0735-1097(17)35106-9

Authors: Ilana Schlam, Ali Huda, Sarah H. Min, Christopher Mahida, Parth Shah, Ping Wang, Naila Goldenberg, Charles Glueck

Institution: Jewish Hospital

Language: English

Topic: Lipoproteins and Cardiovascular Health

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2596954286

FWCI:

Cites:

Cited by:

Related to: 10